globenewswire news

iMDx to Participate in Lake Street 10th Annual Best Ideas Growth “BIG10” Conference

2026-09-02T12:00:00Z

NASHVILLE, Tenn., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced participation in the upcoming Lake Street Capital Markets 10^th Annual Best Ideas Growth “BIG10” Conference taking place September 10^th, 2026 in New York.

Event: Lake Street Capital Markets 10^th Annual Best Ideas Growth “BIG10” Conference
Who: Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James
Date: Thursday, September 10, 2026
Location: Metropolitan Club, New York City
Format: One-on-one meetings

Investors wishing to meet with IMDX management are encouraged to reach out to their Lake Street sales representative.

About Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. Investors may visit https://investors.imdxinc.com/ for more information.

GraftAssureCore™, GraftAssureIQ™, GraftAssureDx™, VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Insight Molecular Diagnostics Inc.

Investor Contact:
Alexandra Grossman
LifeSci Advisors LLC
imdx@lifesciadvisors.com

Articles

Life Line Screening Offers Blood Test That May Provide Early Insight Into Alzheimer’s Disease Risk

2026-09-02T13:06:34Z

A simple blood test that measures an Alzheimer’s-related biomarker may help adults 55 and older decide whether further evaluation is appropriate, even before symptoms appear

Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds

2026-09-02T13:02:00Z

RAMAT GAN, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) (“Can-Fite” or the “Company”), a clinical-stage biotechnology company developing a pipeline of proprietary...

HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment

2026-09-02T13:00:00Z

HCW9302 is a best-in-class IL-2-based immunotherapeutic for treatment of autoimmune diseases through expanding and activating regulatory T cells

AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041

2026-09-02T12:43:00Z

Patent protections establish long-duration intellectual property coverage for Ampligen across major European markets and the United Kingdom

AiM Medical Robotics Awarded $2 Million National Cancer Institute Grant to Advance MRI-Guided Robotic Treatment of Brain Cancer

2026-09-02T12:40:00Z

$2.1M NIH SBIR Phase II grant supports development of AiM’s MRI-compatible neurosurgical robotic platform for precision delivery of ablative brain cancer therapies

Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker

2026-09-02T12:30:00Z

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for...

SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer

2026-09-02T12:30:00Z

- Three posters to highlight preclinical activity of SLS009 (tambiciclib) across patient-derived KRAS mutant organoid models of pancreatic cancer –

MannKind to Present at Upcoming Investor Conferences

2026-09-02T12:30:00Z

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced that members of the MannKind management team will present at the following upcoming investor...

ENvue Medical Selected to Exhibit ENvue™ Navigation Platform at Vizient Innovative Technology Exchange

2026-09-02T12:30:00Z

TYLER, Texas, Sept. 02, 2026 (GLOBE NEWSWIRE) -- ENvue Medical (NASDAQ: FEED) (“ENvue” or the “Company”), a commercial-stage medical device company focused on real-time guided bedside feeding tube placement, today...

RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th

2026-09-02T12:30:00Z

MOUNTAIN VIEW, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a...

Caring Brands Inc. (Nasdaq: CABR) Completes Initial $4.6 Million Closing Under Ongoing $9 Million Private Placement

2026-09-02T12:30:00Z

According To Company’s Recent 8K, The Company Initially Closed On $4.6 Million Of A $9.0 Million Round That Is In Progress On A Rolling Basis

Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference

2026-09-02T12:30:00Z

MIAMI, FL, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory...

Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September

2026-09-02T12:30:00Z

SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for...

Equillium to Participate in Upcoming Investor Conferences

2026-09-02T12:30:00Z

LA JOLLA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management...

SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies

2026-09-02T12:17:00Z

This strategic engagement is designed to strengthen NeuroThera’s U.S. market position, visibility among key U.S. federal stakeholders, reinforce the clinical and public‑health importance of advancing new treatment options for adult...

CG Oncology to Present at Upcoming Investor Conferences in September

2026-09-02T12:00:00Z

DALLAS, Sept. 02, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentations at...

BioAge Labs to Present at Upcoming Investor Conferences

2026-09-02T12:00:00Z

EMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for cardiometabolic diseases by targeting the...

Disc Medicine to Participate in Upcoming Investor Conferences

2026-09-02T12:00:00Z

WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from...

vTv Therapeutics to Participate in September Investor Conferences

2026-09-02T12:00:00Z

HIGH POINT, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D),...

Amlogenyx to Present at the Wells Fargo 21ˢᵗ Annual Healthcare Conference

2026-09-02T12:00:00Z

NOVATO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Amlogenyx, Inc., a biotechnology company focused on developing gene therapies for Alzheimer’s disease and other neurodegenerative diseases, today announced members of the...

Ascentage Pharma to Participate in Four Upcoming Investor Conferences

2026-09-02T12:00:00Z

ROCKVILLE, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biopharmaceutical company engaged in the...